The Role of PPARs in Lung Fibrosis

Lakatos, Heather F.; Thatcher, Thomas H.; Kottmann, R. Matthew; Garcia, Tatiana M.; Phipps, Richard P.; Sime, Patricia J.

doi:https://doi.org/10.1155/2007/71323

PPAR Research

On this page

Abstract References Copyright Related Articles

Special Issue

PPARs in Lung Biology and Disease

View this Special Issue

Review Article | Open Access

Volume 2007 | Article ID 071323 | https://doi.org/10.1155/2007/71323

The Role of PPARs in Lung Fibrosis

Heather F. Lakatos,^1,2Thomas H. Thatcher,^2,3R. Matthew Kottmann,^2,3Tatiana M. Garcia,^2,4Richard P. Phipps,^1,2,4and Patricia J. Sime^1,2,3

Academic Editor: Jesse Roman

Received14 Feb 2007

Accepted18 May 2007

Published02 Jul 2007

Abstract

Pulmonary fibrosis is a group of disorders characterized by accumulation of scar tissue in the lung interstitium, resulting in loss of alveolar function, destruction of normal lung architecture, and respiratory distress. Some types of fibrosis respond to corticosteroids, but for many there are no effective treatments. Prognosis varies but can be poor. For example, patients with idiopathic pulmonary fibrosis (IPF) have a median survival of only 2.9 years. Prognosis may be better in patients with some other types of pulmonary fibrosis, and there is variability in survival even among individuals with biopsy-proven IPF. Evidence is accumulating that the peroxisome proliferator-activated receptors (PPARs) play important roles in regulating processes related to fibrogenesis, including cellular differentiation, inflammation, and wound healing. PPARα agonists, including the hypolidipemic fibrate drugs, inhibit the production of collagen by hepatic stellate cells and inhibit liver, kidney, and cardiac fibrosis in animal models. In the mouse model of lung fibrosis induced by bleomycin, a PPARα agonist significantly inhibited the fibrotic response, while PPARα knockout mice developed more serious fibrosis. PPARβ/δ appears to play a critical role in regulating the transition from inflammation to wound healing. PPARβ/δ agonists inhibit lung fibroblast proliferation and enhance the antifibrotic properties of PPARγ agonists. PPARγ ligands oppose the profibrotic effect of TGF-β, which induces differentiation of fibroblasts to myofibroblasts, a critical effector cell in fibrosis. PPARγ ligands, including the thiazolidinedione class of antidiabetic drugs, effectively inhibit lung fibrosis in vitro and in animal models. The clinical availability of potent and selective PPARα and PPARγ agonists should facilitate rapid development of successful treatment strategies based on current and ongoing research.

References

V. J. Thannickal, G. B. Toews, E. S. White, J. P. Lynch III, and F. J. Martinez, “Mechanisms of pulmonary fibrosis,” Annual Review of Medicine, vol. 55, pp. 395–417, 2004.
View at: Publisher Site | Google Scholar
P. J. Sime and K. M. A. O'Reilly, “Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment,” Clinical Immunology, vol. 99, no. 3, pp. 308–319, 2001.
View at: Publisher Site | Google Scholar
T. Geiser, “Idiopathic pulmonary fibrosis—a disorder of alveolar wound repair?” Swiss Medical Weekly, vol. 133, no. 29-30, pp. 405–411, 2003.
View at: Google Scholar
N. Fujimura, “Pathology and pathophysiology of pneumoconiosis,” Current Opinion in Pulmonary Medicine, vol. 6, no. 2, pp. 140–144, 2000.
View at: Publisher Site | Google Scholar
B. T. Mossman and A. Churg, “Mechanisms in the pathogenesis of asbestosis and silicosis,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 5, part 1, pp. 1666–1680, 1998.
View at: Google Scholar
D. A. Zisman, M. P. Keane, J. A. Belperio, R. M. Strieter, and J. P. Lynch III, “Pulmonary fibrosis,” Methods in Molecular Medicine, vol. 117, pp. 3–44, 2005.
View at: Google Scholar
K. B. Baumgartner, J. M. Samet, D. B. Coultas et al., “Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers,” American Journal of Epidemiology, vol. 152, no. 4, pp. 307–315, 2000.
View at: Publisher Site | Google Scholar
K. B. Baumgartner, J. M. Samet, C. A. Stidley, T. V. Colby, and J. A. Waldron, “Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 1, pp. 242–248, 1997.
View at: Google Scholar
E. S. White, M. H. Lazar, and V. J. Thannickal, “Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis,” Journal of Pathology, vol. 201, no. 3, pp. 343–354, 2003.
View at: Publisher Site | Google Scholar
P. de Vuyst and P. Camus, “The past and present of pneumoconioses,” Current Opinion in Pulmonary Medicine, vol. 6, no. 2, pp. 151–156, 2000.
View at: Publisher Site | Google Scholar
H. R. Collard, J. H. Ryu, W. W. Douglas et al., “Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis,” Chest, vol. 125, no. 6, pp. 2169–2174, 2004.
View at: Publisher Site | Google Scholar
J. J. Swigris, W. G. Kuschner, J. L. Kelsey, and M. K. Gould, “Idiopathic pulmonary fibrosis: challenges and opportunities for the clinician and investigator,” Chest, vol. 127, no. 1, pp. 275–283, 2005.
View at: Publisher Site | Google Scholar
D. S. Kim, H. R. Collard, and T. E. King Jr., “Classification and natural history of the idiopathic interstitial pneumonias,” Proceedings of the American Thoracic Society, vol. 3, no. 4, pp. 285–292, 2006.
View at: Publisher Site | Google Scholar
S. H. Phan, “The myofibroblast in pulmonary fibrosis,” Chest, vol. 122, 6, pp. 286S–289S, 2002.
View at: Publisher Site | Google Scholar
R. S. Smith, T. J. Smith, T. M. Blieden, and R. P. Phipps, “Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation,” American Journal of Pathology, vol. 151, no. 2, pp. 317–322, 1997.
View at: Google Scholar
M. B. Vaughan, E. W. Howard, and J. J. Tomasek, “Transforming growth factor- $β$ 1 promotes the morphological and functional differentiation of the myofibroblast,” Experimental Cell Research, vol. 257, no. 1, pp. 180–189, 2000.
View at: Publisher Site | Google Scholar
G. Gabbiani, “The myofibroblast in wound healing and fibrocontractive diseases,” Journal of Pathology, vol. 200, no. 4, pp. 500–503, 2003.
View at: Publisher Site | Google Scholar
S. H. Phan, K. Zhang, H. Y. Zhang, and M. Gharaee-Kermani, “The myofibroblast as an inflammatory cell in pulmonary fibrosis,” Current Topics in Pathology, vol. 93, pp. 173–182, 1999.
View at: Google Scholar
M. Selman, T. E. King Jr., and A. Pardo, “Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy,” Annals of Internal Medicine, vol. 134, no. 2, pp. 136–151, 2001.
View at: Google Scholar
J. Gauldie, M. Kolb, and P. J. Sime, “A new direction in the pathogenesis of idiopathic pulmonary fibrosis?” Respiratory Research, vol. 3, p. 1, 2001.
View at: Publisher Site | Google Scholar
U. Bartram and C. P. Speer, “The role of transforming growth factor $β$ in lung development and disease,” Chest, vol. 125, no. 2, pp. 754–765, 2004.
View at: Publisher Site | Google Scholar
M. Kelly, M. Kolb, P. Bonniaud, and J. Gauldie, “Re-evaluation of fibrogenic cytokines in lung fibrosis,” Current Pharmaceutical Design, vol. 9, no. 1, pp. 39–49, 2003.
View at: Publisher Site | Google Scholar
H.-Y. Zhang and S. H. Phan, “Inhibition of myofibroblast apoptosis by transforming growth factor $β_{1}$ ,” American Journal of Respiratory Cell and Molecular Biology, vol. 21, no. 6, pp. 658–665, 1999.
View at: Google Scholar
P. J. Sime, Z. Xing, F. L. Graham, K. G. Csaky, and J. Gauldie, “Adenovector-mediated gene transfer of active transforming growth factor- $β_{1}$ induces prolonged severe fibrosis in rat lung,” Journal of Clinical Investigation, vol. 100, no. 4, pp. 768–776, 1997.
View at: Google Scholar
C. Blanquart, O. Barbier, J. C. Fruchart, B. Staels, and C. Glineur, “Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation,” Journal of Steroid Biochemistry and Molecular Biology, vol. 85, no. 2–5, pp. 267–273, 2003.
View at: Publisher Site | Google Scholar
I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.
View at: Publisher Site | Google Scholar
O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR- $α$ , - $β$ , and - $γ$ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996.
View at: Publisher Site | Google Scholar
M. Ricote, J. Huang, L. Fajas et al., “Expression of the peroxisome proliferator-activated receptor $?$ (PPAR $?$ ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7614–7619, 1998.
View at: Publisher Site | Google Scholar
S. G. Harris, J. Padilla, L. Koumas, D. Ray, and R. P. Phipps, “Prostaglandins as modulators of immunity,” Trends in Immunology, vol. 23, no. 3, pp. 144–150, 2002.
View at: Publisher Site | Google Scholar
J. Padilla, E. Leung, and R. P. Phipps, “Human B lymphocytes and B lymphomas express PPAR- $γ$ and are killed by PPAR- $γ$ agonists,” Clinical Immunology, vol. 103, no. 1, pp. 22–33, 2002.
View at: Publisher Site | Google Scholar
F. Akbiyik, D. M. Ray, K. F. Gettings, N. Blumberg, C. W. Francis, and R. P. Phipps, “Human bone marrow megakaryocytes and platelets express PPAR $γ$ , and PPAR $γ$ agonists blunt platelet release of CD40 ligand and thromboxanes,” Blood, vol. 104, no. 5, pp. 1361–1368, 2004.
View at: Publisher Site | Google Scholar
D. M. Simon, M. C. Arikan, S. Srisuma et al., “Epithelial cell PPAR $?$ is an endogenous regulator of normal lung maturation and maintenance,” Proceedings of the American Thoracic Society, vol. 3, no. 6, pp. 510–511, 2006.
View at: Publisher Site | Google Scholar
D. M. Simon, M. C. Arikan, S. Srisuma et al., “Epithelial cell PPAR $?$ contributes to normal lung maturation,” The FASEB Journal, vol. 20, no. 9, pp. 1507–1509, 2006.
View at: Publisher Site | Google Scholar
E. Marian, S. Baraldo, A. Visentin et al., “Up-regulated membrane and nuclear leukotriene B4 receptors in COPD,” Chest, vol. 129, no. 6, pp. 1523–1530, 2006.
View at: Publisher Site | Google Scholar
D. A. Culver, B. P. Barna, B. Raychaudhuri et al., “Peroxisome proliferator-activated receptor $?$ activity is deficient in alveolar macrophages in pulmonary sarcoidosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 30, no. 1, pp. 1–5, 2004.
View at: Publisher Site | Google Scholar
T. L. Bonfield, C. F. Farver, B. P. Barna et al., “Peroxisome proliferator-activated receptor- $?$ is deficient in alveolar macrophages from patients with alveolar proteinosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 29, no. 6, pp. 677–682, 2003.
View at: Publisher Site | Google Scholar
G. Rizzo and S. Fiorucci, “PPARs and other nuclear receptors in inflammation,” Current Opinion in Pharmacology, vol. 6, no. 4, pp. 421–427, 2006.
View at: Publisher Site | Google Scholar
T. Sher, H.-F. Yi, O. W. McBride, and F. J. Gonzalez, “cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor,” Biochemistry, vol. 32, no. 21, pp. 5598–5604, 1993.
View at: Publisher Site | Google Scholar
S. Cuzzocrea, “Peroxisome proliferator-activated receptors and acute lung injury,” Current Opinion in Pharmacology, vol. 6, no. 3, pp. 263–270, 2006.
View at: Publisher Site | Google Scholar
T. Toyama, H. Nakamura, Y. Harano et al., “PPAR $a$ ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats,” Biochemical and Biophysical Research Communications, vol. 324, no. 2, pp. 697–704, 2004.
View at: Publisher Site | Google Scholar
G. Svegliati-Baroni, C. Candelaresi, S. Saccomanno et al., “A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor- $a$ and n-3 polyunsaturated fatty acid treatment on liver injury,” American Journal of Pathology, vol. 169, no. 3, pp. 846–860, 2006.
View at: Publisher Site | Google Scholar
E. Ip, G. Farrell, P. Hall, G. Robertson, and I. Leclercq, “Administration of the potent PPAR $α$ agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice,” Hepatology, vol. 39, no. 5, pp. 1286–1296, 2004.
View at: Publisher Site | Google Scholar
T. Ogata, T. Miyauchi, S. Sakai, Y. Irukayama-Tomobe, K. Goto, and I. Yamaguchi, “Stimulation of peroxisome-proliferator-activated receptor $α$ (PPAR $α$ ) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts,” Clinical Science, vol. 103, 48, pp. 284S–288S, 2002.
View at: Google Scholar
M. Iglarz, R. M. Touyz, E. C. Viel et al., “Peroxisome proliferator-activated receptor- $a$ and receptor- $?$ activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension,” Hypertension, vol. 42, no. 4, pp. 737–743, 2003.
View at: Publisher Site | Google Scholar
A. C. Calkin, S. Giunti, K. A. Jandeleit-Dahm, T. J. Allen, M. E. Cooper, and M. C. Thomas, “PPAR- $α$ and - $γ$ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse,” Nephrology Dialysis Transplantation, vol. 21, no. 9, pp. 2399–2405, 2006.
View at: Publisher Site | Google Scholar
V. Reynders, S. Loitsch, C. Steinhauer, T. Wagner, D. Steinhilber, and J. Bargon, “Peroxisome proliferator-activated receptor $α$ (PPAR $α$ ) down-regulation in cystic fibrosis lymphocytes,” Respiratory Research, vol. 7, p. 104, 2006.
View at: Publisher Site | Google Scholar
S. Cuzzocrea, E. Mazzon, R. Di Paola et al., “The role of the peroxisome proliferator-activated receptor- $a$ (PPAR- $a$ ) in the regulation of acute inflammation,” Journal of Leukocyte Biology, vol. 79, no. 5, pp. 999–1010, 2006.
View at: Publisher Site | Google Scholar
T. H. Thatcher, P. J. Sime, and R. K. Barth, “Sensitivity to bleomycin-induced lung injury is not moderated by an antigen-limited T-cell repertoire,” Experimental Lung Research, vol. 31, no. 7, pp. 685–700, 2005.
View at: Publisher Site | Google Scholar
D. H. Bowden, “Unraveling pulmonary fibrosis: the bleomycin model,” Laboratory Investigation, vol. 50, no. 5, pp. 487–488, 1984.
View at: Google Scholar
T. Genovese, E. Mazzon, R. Di Paola et al., “Role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor $a$ in the development of bleomycin-induced lung injury,” Shock, vol. 24, no. 6, pp. 547–555, 2006.
View at: Publisher Site | Google Scholar
E. Dyrøy, A. Yndestad, T. Ueland et al., “Antiinflammatory effects of tetradecylthioacetic acid involve both peroxisome proliferator-activated receptor $a$ -dependent and -independent pathways,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 7, pp. 1364–1369, 2005.
View at: Publisher Site | Google Scholar
J. M. Lehmann, J. M. Lenhard, B. B. Oliver, G. M. Ringold, and S. A. Kliewer, “Peroxisome proliferator-activated receptors $α$ and $γ$ are activated by indomethacin and other non-steroidal anti-inflammatory drugs,” Journal of Biological Chemistry, vol. 272, no. 6, pp. 3406–3410, 1997.
View at: Publisher Site | Google Scholar
L. Michalik, B. Desvergne, N. S. Tan et al., “Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) $a$ and PPAR $ß$ mutant mice,” Journal of Cell Biology, vol. 154, no. 4, pp. 799–814, 2001.
View at: Publisher Site | Google Scholar
N. S. Tan, L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome proliferator-activated receptor- $β$ as a target for wound healing drugs,” Expert Opinion on Therapeutic Targets, vol. 8, no. 1, pp. 39–48, 2004.
View at: Publisher Site | Google Scholar
F. Y. Ali, K. Egan, G. A. FitzGerald et al., “Role of prostacyclin versus peroxisome proliferator-activated receptor $ß$ receptors in prostacyclin sensing by lung fibroblasts,” American Journal of Respiratory Cell and Molecular Biology, vol. 34, no. 2, pp. 242–246, 2006.
View at: Publisher Site | Google Scholar
K. Matsusue, J. M. Peters, and F. J. Gonzalez, “PPAR $β$ / $δ$ potentiates PPAR $γ$ -stimulated adipocyte differentiation,” The FASEB Journal, vol. 18, no. 12, pp. 1477–1479, 2004.
View at: Publisher Site | Google Scholar
T. H.-W. Huang, V. Razmovski-Naumovski, B. P. Kota, D. S.-H. Lin, and B. D. Roufogalis, “The pathophysiological function of peroxisome proliferator-activated receptor- $γ$ in lung-related diseases,” Respiratory Research, vol. 6, p. 102, 2005.
View at: Publisher Site | Google Scholar
B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy- $Δ^{12, 14}$ -prostaglandin $J_{2}$ is a ligand for the adipocyte determination factor PPAR $γ$ ,” Cell, vol. 83, no. 5, pp. 803–812, 1995.
View at: Publisher Site | Google Scholar
S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann, “A prostaglandin $J_{2}$ metabolite binds peroxisome proliferator-activated receptor $γ$ and promotes adipocyte differentiation,” Cell, vol. 83, no. 5, pp. 813–819, 1995.
View at: Publisher Site | Google Scholar
T. M. McIntyre, A. V. Pontsler, A. R. Silva et al., “Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPAR $?$ agonist,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 1, pp. 131–136, 2003.
View at: Publisher Site | Google Scholar
F. J. Schopfer, Y. Lin, P. R. S. Baker et al., “Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor $?$ ligand,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 7, pp. 2340–2345, 2005.
View at: Publisher Site | Google Scholar
J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor $γ$ (PPAR $γ$ ),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995.
View at: Publisher Site | Google Scholar
A. E. Place, N. Suh, C. R. Williams et al., “The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo,” Clinical Cancer Research, vol. 9, no. 7, pp. 2798–2806, 2003.
View at: Google Scholar
M. G. Belvisi, D. J. Hele, and M. A. Birrell, “Peroxisome proliferator-activated receptor $γ$ agonists as therapy for chronic airway inflammation,” European Journal of Pharmacology, vol. 533, no. 1–3, pp. 101–109, 2006.
View at: Publisher Site | Google Scholar
D. Liu, B. X. Zeng, S. H. Zhang, and S. L. Yao, “Rosiglitazone, an agonist of peroxisome proliferator-activated receptor $γ$ , reduces pulmonary inflammatory response in a rat model of endotoxemia,” Inflammation Research, vol. 54, no. 11, pp. 464–470, 2005.
View at: Publisher Site | Google Scholar
K.-I. Inoue, H. Takano, R. Yanagisawa et al., “Effect of 15-deoxy- $?^{12, 14}$ -prostaglandin $J_{2}$ on acute lung injury induced by lipopolysaccharide in mice,” European Journal of Pharmacology, vol. 481, no. 2-3, pp. 261–269, 2003.
View at: Publisher Site | Google Scholar
J. E. Ward, D. J. Fernandes, C. C. Taylor, J. V. Bonacci, L. Quan, and A. G. Stewart, “The PPAR $γ$ ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation,” Pulmonary Pharmacology and Therapeutics, vol. 19, no. 1, pp. 39–46, 2006.
View at: Publisher Site | Google Scholar
K. Honda, P. Marquillies, M. Capron, and D. Dombrowicz, “Peroxisome proliferator-activated receptor $γ$ is expressed in airways and inhibits features of airway remodeling in a mouse asthma model,” Journal of Allergy and Clinical Immunology, vol. 113, no. 5, pp. 882–888, 2004.
View at: Publisher Site | Google Scholar
C. Jiang, A. T. Ting, and B. Seed, “PPAR- $γ$ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998.
View at: Publisher Site | Google Scholar
A. C. C. Wang, X. Dai, B. Luu, and D. J. Conrad, “Peroxisome proliferator-activated receptor- $γ$ regulates airway epithelial cell activation,” American Journal of Respiratory Cell and Molecular Biology, vol. 24, no. 6, pp. 688–693, 2001.
View at: Google Scholar
S. E. Feldon, C. W. O'Loughlin, D. M. Ray, S. Landskroner-Eiger, K. E. Seweryniak, and R. P. Phipps, “Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes,” American Journal of Pathology, vol. 169, no. 4, pp. 1183–1193, 2006.
View at: Publisher Site | Google Scholar
I. A. Leclercq, C. Sempoux, P. Stärkel, and Y. Horsmans, “Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats,” Gut, vol. 55, no. 7, pp. 1020–1029, 2006.
View at: Publisher Site | Google Scholar
K. Kawaguchi, I. Sakaida, M. Tsuchiya, K. Omori, T. Takami, and K. Okita, “Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet,” Biochemical and Biophysical Research Communications, vol. 315, no. 1, pp. 187–195, 2004.
View at: Publisher Site | Google Scholar
H. Uto, C. Nakanishi, A. Ido et al., “The peroxisome proliferator-activated receptor- $?$ agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, L-amino acid-defined diet,” Hepatology Research, vol. 32, no. 4, pp. 235–242, 2005.
View at: Publisher Site | Google Scholar
R. E. Buckingham, “Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection,” Hepatology Research, vol. 33, no. 2, pp. 167–170, 2005.
View at: Publisher Site | Google Scholar
M. C. Lansang, C. Coletti, S. Ahmed, M. S. Gordon, and N. K. Hollenberg, “Effects of the PPAR- $γ$ agonist rosiglitazone on renal haemodynamics and the renin-angiotensin system in diabetes,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 7, no. 3, pp. 175–180, 2006.
View at: Google Scholar
T. Genovese, S. Cuzzocrea, R. Di Paola et al., “Effect of rosiglitazone and 15-deoxy- $?^{12, 14}$ -prostaglandin $J_{2}$ on bleomycin-induced lung injury,” European Respiratory Journal, vol. 25, no. 2, pp. 225–234, 2005.
View at: Publisher Site | Google Scholar
Y. Barak, M. C. Nelson, E. S. Ong et al., “PPAR $?$ is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999.
View at: Publisher Site | Google Scholar
H. A. Burgess, L. E. Daugherty, T. H. Thatcher et al., “PPAR $?$ agonists inhibit TGF- $ß$ induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis,” American Journal of Physiology, vol. 288, no. 6, pp. L1146–L1153, 2005.
View at: Publisher Site | Google Scholar
T. Miyahara, L. Schrum, R. Rippe et al., “Peroxisome proliferator-activated receptors and hepatic stellate cell activation,” Journal of Biological Chemistry, vol. 275, no. 46, pp. 35715–35722, 2000.
View at: Publisher Site | Google Scholar
M. L. Hautekeete and A. Geerts, “The hepatic stellate (Ito) cell: its role in human liver disease,” Virchows Archiv, vol. 430, no. 3, pp. 195–207, 1997.
View at: Publisher Site | Google Scholar
D. M. Bissell, “Connective tissue metabolism and hepatic fibrosis: an overview,” Seminars in Liver Disease, vol. 10, no. 1, pp. iii–iv, 1990.
View at: Google Scholar
F. Marra, E. Efsen, R. G. Romanelli et al., “Ligands of peroxisome proliferator-activated receptor $?$ modulate profibrogenic and proinflammatory actions in hepatic stellate cells,” Gastroenterology, vol. 119, no. 2, pp. 466–478, 2000.
View at: Publisher Site | Google Scholar
Y. Li, X. Wen, B. C. Spataro, K. Hu, C. Dai, and Y. Liu, “Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor- $γ$ agonists,” Journal of the American Society of Nephrology, vol. 17, no. 1, pp. 54–65, 2006.
View at: Publisher Site | Google Scholar
A. Masamune, K. Satoh, Y. Sakai, M. Yoshida, A. Satoh, and T. Shimosegawa, “Ligands of peroxisome proliferator-activated receptor- $γ$ induce apoptosis in AR42J cells,” Pancreas, vol. 24, no. 2, pp. 130–138, 2002.
View at: Publisher Site | Google Scholar
S. Zafiriou, S. R. Stanners, S. Saad, T. S. Polhill, P. Poronnik, and C. A. Pollock, “Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts,” Journal of the American Society of Nephrology, vol. 16, no. 3, pp. 638–645, 2005.
View at: Publisher Site | Google Scholar
U. Panchapakesan, S. Sumual, C. A. Pollock, and X. Chen, “PPAR $γ$ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose,” American Journal of Physiology, vol. 289, no. 5, pp. F1153–F1158, 2005.
View at: Publisher Site | Google Scholar
C. Zhao, W. Chen, L. Yang, L. Chen, S. A. Stimpson, and A. M. Diehl, “PPAR $γ$ agonists prevent TGF $β$ 1/Smad3-signaling in human hepatic stellate cells,” Biochemical and Biophysical Research Communications, vol. 350, no. 2, pp. 385–391, 2006.
View at: Publisher Site | Google Scholar
S. J. Lee, E. K. Yang, and S. G. Kim, “Peroxisome proliferator-activated receptor- $γ$ and retinoic acid X receptor $α$ represses the TGF $β$ 1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation,” Molecular Pharmacology, vol. 70, no. 1, pp. 415–425, 2006.
View at: Publisher Site | Google Scholar
R. E. Teresi, C.-W. Shaiu, C.-S. Chen, V. K. Chatterjee, K. A. Waite, and C. Eng, “Increased PTEN expression due to transcriptional activation of PPAR $γ$ by Lovastatin and Rosiglitazone,” International Journal of Cancer, vol. 118, no. 10, pp. 2390–2398, 2006.
View at: Publisher Site | Google Scholar
E. S. White, R. G. Atrasz, B. Hu et al., “Negative regulation of myofibroblast differentiation by PTEN (phosphatase and tensin homolog deleted on chromosome 10),” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 1, pp. 112–121, 2006.
View at: Publisher Site | Google Scholar
E. S. White, V. J. Thannickal, S. L. Carskadon et al., “Integrin $a$ 4 $ß$ 1 regulates migration across basement membranes by lung fibroblasts: a role for phosphatase and tensin homologue deleted on chromosome 10,” American Journal of Respiratory and Critical Care Medicine, vol. 168, no. 4, pp. 436–442, 2003.
View at: Publisher Site | Google Scholar
Y. Zuo, L. Qiang, and S. R. Farmer, “Activation of CCAAT/enhancer-binding protein (C/EBP) $α$ expression by C/EBP $β$ during adipogenesis requires a peroxisome proliferator-activated receptor- $γ$ -associated repression of HDAC1 at the C/ebp $α$ gene promoter,” Journal of Biological Chemistry, vol. 281, no. 12, pp. 7960–7967, 2006.
View at: Publisher Site | Google Scholar
S. S. Chung, H. H. Choi, Y. M. Cho, H. K. Lee, and K. S. Park, “Sp1 mediates repression of the resistin gene by PPAR $γ$ agonists in 3T3-L1 adipocytes,” Biochemical and Biophysical Research Communications, vol. 348, no. 1, pp. 253–258, 2006.
View at: Publisher Site | Google Scholar
J. Atsmon, B. J. Sweetman, S. W. Baertschi, T. M. Harris, and L. J. Roberts II, “Formation of thiol conjugates of 9-deoxy- $Δ^{9}$ , $Δ^{12}$ ( $E$ )-prostaglandin $D_{2}$ and $Δ^{12}$ ( $E$ )-prostaglandin $D_{2}$ ,” Biochemistry, vol. 29, no. 15, pp. 3760–3765, 1990.
View at: Publisher Site | Google Scholar
T. Shibata, T. Yamada, T. Ishii et al., “Thioredoxin as a molecular target of cyclopentenone prostaglandins,” Journal of Biological Chemistry, vol. 278, no. 28, pp. 26046–26054, 2003.
View at: Publisher Site | Google Scholar
K. Shimizu, K. Shiratori, M. Kobayashi, and H. Kawamata, “Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPAR $γ$ - independent mechanism,” Pancreas, vol. 29, no. 1, pp. 67–74, 2004.
View at: Publisher Site | Google Scholar
H.-J. Kim, J.-Y. Kim, Z. Meng et al., “15-deoxy- $?^{12, 14}$ -prostaglandin $J_{2}$ inhibits transcriptional activity of estrogen receptor- $a$ via covalent modification of DNA-binding domain,” Cancer Research, vol. 67, no. 6, pp. 2595–2602, 2007.
View at: Publisher Site | Google Scholar
I. Issemann, R. A. Prince, J. D. Tugwood, and S. Green, “The peroxisome proliferator-activated receptor: retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs,” Journal of Molecular Endocrinology, vol. 11, no. 1, pp. 37–47, 1993.
View at: Google Scholar
H. S. Ahuja, A. Szanto, L. Nagy, and P. J. A. Davies, “The retinoid X receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death,” Journal of Biological Regulators and Homeostatic Agents, vol. 17, no. 1, pp. 29–45, 2003.
View at: Google Scholar
P. Germain, P. Chambon, G. Eichele et al., “International union of pharmacology. LXIII. Retinoid X receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 760–772, 2006.
View at: Publisher Site | Google Scholar
K. Hellemans, P. Verbuyst, E. Quartier et al., “Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids,” Hepatology, vol. 39, no. 1, pp. 97–108, 2004.
View at: Publisher Site | Google Scholar
M. Ohata, M. Lin, M. Satre, and H. Tsukamoto, “Diminished retinoic acid signaling in hepatic stellate cells in cholestatic liver fibrosis,” American Journal of Physiology, vol. 272, no. 3, part 1, pp. G589–G596, 1997.
View at: Google Scholar
X. Wen, Y. Li, K. Hu, C. Dai, and Y. Liu, “Hepatocyte growth factor receptor signaling mediates the anti-fibrotic action of 9-cis-retinoic acid in glomerular mesangial cells,” American Journal of Pathology, vol. 167, no. 4, pp. 947–957, 2005.
View at: Google Scholar
G. Chinetti, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications,” International Journal of Obesity and Related Metabolic Disorders, vol. 27, 3, pp. S41–S45, 2003.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2007 Heather F. Lakatos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

1268

Downloads

1612

Citations